By 2030, OSD Contract Manufacturing Will Be $54.7 Billion

The global oral solid dosage (OSD) contract manufacturing market is anticipated to reach $54.7 billion in value by 2030, exhibiting a compound annual growth rate (CAGR) of 6%, according to a market analysis.

As per data, oral solids are the most widely used drug delivery method globally since they are very affordable and have straightforward manufacturing procedures. As these types minimise the conventional dosage regularity for patients, who only need to take these meds, say, once a week, slow-release versions were a popular choice for manufacturers. This has the added benefit of reducing any negative effects.

Because of their ease of creation, delivery, and mobility to the final user, tablets were predicted to be the most popular OSD in 2021. According to the report, there is a growing market for bilayer tablets in particular.

As per research, the market value was increased by huge contract manufacturing organisations (CMOs), who invested heavily in R&D, as well as contract development and manufacturing organisations (CDMOs). Since pharmaceutical companies choose to outsource jobs to these organisations even in the early stages of drug manufacture, large CMOs accounted for the largest percentage of revenue in 2021.

Clinical-stage cancer programmes grew significantly between the years 2015 and 2020 (1,642 to 2,911), culminating in a quarter of the medicines now under development being highly powerful. It’s difficult for many pharmaceutical companies to change their installed capacity because of the increased need for small-scale and enclosed manufacturing processes required to construct these products.

The COVID-19 pandemic reduced the healthcare industry’s revenue in 2020 as a result of labour shortages and a significant disruption to the supply chain for raw materials.

However, this demonstrated to industry leaders the significance of R&D for medications meant to combat viral infections, paving the way for this market segment to grow in the years that followed. Azithromycin and hydroxychloroquine, two small-molecule oral solids that have been shown to be effective in treating COVID-19 patients, have been crucial in reviving the market. Since then, additional businesses have concentrated on developing and manufacturing OSD medications through agreements with CMOs. Increased collaboration, flexibility, and adaptability have consequently been key elements influencing the solid dose manufacturing business.

In 2021, Asia-Pacific led the world market as a whole, and it is predicted that it would continue to lead over the ensuing projected period with the highest CAGR. China and India have helped to dominate the OSD CMO industry by operating in a market with extremely low prices.